|Other Names||Carboxypeptidase A4, 3417-, Carboxypeptidase A3, CPA4, CPA3|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7338b was selected from the C-term region of human CPA4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Metalloprotease that could be involved in the histone hyperacetylation pathway.|
|Tissue Location||Fetal expression in the adrenal gland, brain, heart, intestine, kidney, liver and lung. Except for fetal brain that shows no imprinting, expression was found preferentially from the maternal allele|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CPA4 is a member of the carboxypeptidase A/B subfamily. Carboxypeptidases are zinc-containing exopeptidases that catalyze the release of carboxy-terminal amino acids, and are synthesized as zymogens that are activated by proteolytic cleavage. This protein could be involved in the histone hyperacetylation pathway. It is imprinted and may be a strong candidate protein for prostate cancer aggressiveness.
Ross,P.L., Cheng,I. BMC Cancer 9, 69 (2009)Bentley,L., Nakabayashi,K. J. Med. Genet. 40 (4), 249-256 (2003)Kayashima,T., Yamasaki,K. Hum. Genet. 112 (3), 220-226 (2003)Hayashida,S., Yamasaki,K. Genomics 66 (2), 221-225 (2000)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.